scispace - formally typeset
Search or ask a question

Showing papers by "Giulia Pasello published in 2014"


Journal ArticleDOI
TL;DR: Everolimus may induce durable disease control in a high percentage of patients with T or TC, albeit with a potential high risk of fatal pneumonitis, as evaluated in a single-arm, single-stage, open-label, multicenter, phase II trial.
Abstract: PurposeNo effective salvage treatments are available for patients with advanced/recurrent thymoma (T) or thymic carcinoma (TC) who have progressed after platinum-based chemotherapy. This study evaluated the activity of everolimus in patients with advanced/recurrent T or TC previously treated with cisplatin-containing chemotherapy.Patients and MethodsThis was a single-arm, single-stage, open-label, multicenter, phase II trial. Patients received oral everolimus 10 mg/d until disease progression, unacceptable toxicity, or patient refusal. A Fleming phase II trial was designed. The null hypothesis of a true disease control rate (DCR) of 40% was tested against a one-sided alternative of a true DCR of 60% (α = β = 0.10): If disease control were achieved in ≥ 21 of the first 41 evaluable patients, everolimus could be recommended for further evaluation. Progression-free survival, overall survival, and safety were also evaluated.ResultsFrom 2011 to 2013, 51 patients were enrolled (T, n = 32; TC, n = 19). Complete ...

110 citations


Journal ArticleDOI
TL;DR: Non-epithelioid histology, age ⩾75 years, advanced IMIG stage and presence of comorbidities according to CCI were significant prognostic factors in elderly patients with MPM.
Abstract: Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey

35 citations


Journal ArticleDOI
TL;DR: COPD-related adenocarcinoma presents molecular and morphological features of lower aggressiveness (increased lepidic component, reduced solid pattern, lower cell proliferation and less frequent KRAS mutation) compared to smokers.

19 citations


Journal ArticleDOI
TL;DR: In vitro results suggest that chemotherapy sensitizes MPM to TRAIL-dependent apoptosis through p53 activation and subsequent upregulation of DRs, and in vivo results suggest the opposite is true.

9 citations